Related Experiment Video
Updated: Jan 10, 2026
Isolation of Low Endotoxin Content Extracellular Vesicles Derived from Cancer Cell Lines
Published on: February 17, 2023
Recombinant immunotoxins with low endotoxins for clinical and animal studies
1Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. OndaM@mail.nih.gov
Abstract:
Recombinant immunotoxin (RIT) contains the Fv portion of the antibody fused to the truncated form of toxin and are ongoing in clinical trials for cancer therapy. To obtain high yields of products, RITs are produced in Escherichia coli (E. coli). As the endotoxin came from E. coli cells and is harmful to animals, it is important to produce the RITs with low endotoxin. This section describes the protocols to produce RITs containing low level of endotoxins.
